Clinical Response to Tricyclic Antidepressants in Functional Bowel Disorders is not Related to Dosage

Halpert, Albena; Dalton, Christine B.; Diamant, Nicholas E.; Toner, Brenda B.; Hu, Yuming; Morris, Carolyn B.; Bangdiwala, Shrikant I.; Whitehead, William E.; Drossman, Douglas A.
March 2005
American Journal of Gastroenterology;Mar2005, Vol. 100 Issue 3, p664
Academic Journal
BACKGROUND: As shown in the per protocol analysis of a recent randomized, controlled trial, when tolerated, Desipramine (DES) is effective over placebo (PLA) in treating moderate-to-severe functional bowel disorders (FBD). Clinical experience suggests that the benefit from tricyclic antidepressants (TCA) in FBD can be achieved at doses lower than those used to treat major depression. Within psychiatry, when using higher dosage of TCAs, plasma levels can be used to adjust daily dosage to optimize a treatment response. However, in FBD, it is not known whether plasma levels at the lower dosage are similarly related to a clinical response.AIM: To determine in treating FBD, whether DES blood levels or dose taken can predict a clinical response.METHODS: As part of a study of 12 wk of antidepressant and psychological treatment in 431 patients with FBD at UNC and U of Toronto, we studied those participants who completed treatment (per protocol analysis) taking DES (N= 97, dose 50–150 mg/day) or pill placebo (PLA) (N= 55 1–3 pills/day). The primary outcome measure was defined as a composite score (Satisfaction with Treatment, McGill Pain Questionnaire, Global Well-being, and IBS-QOL). The composite score was correlated with: (i) DES plasma levels at week 6, and (ii) number of pills taken over the duration of the 12-wk treatment period. In addition, we also compared DES dose with DES plasma levels.RESULTS: There was a modest correlation between mean DES dose at weeks 5 and 6 and DES blood level at week 6 (R= 0.2p<0.07). However, there were no significant correlations between the composite score either with DES dose or with DES blood levels.CONCLUSIONS: Detectible blood levels of DES are associated with a clinical response in FBD. However, with dosages up to 150 mg, there is no relationship between total dose or plasma level and the clinical response.(Am J Gastroenterol 2005;100:664–671)


Related Articles

  • Effectiveness of antidepressants. Bollini, Paola; Pampallona, Sandro; Tibaldi, Giuseppe; Kupelnick, Bruce; Munizza, Carmine // British Journal of Psychiatry;Apr99, Vol. 174, p297 

    Background Antidepressant drugs are usually prescribed at low doses, possibly to avoid adverse reactions. No comprehensive review has addressed the issue of dose, clinical response and tolerability in a quantitative way. Aims To determine whether high doses of antidepressants are more effective...

  • Long-term treatment of depression with antidepressants: a systematic narrative review. Furukawa, Toshi A.; Cipriani, Andrea; Barbui, Corrado; Geddes, John R. // Canadian Journal of Psychiatry;Sep2007, Vol. 52 Issue 9, p545 

    Objective: To examine the available scientific evidence for answers to clinically relevant questions on the effectiveness and tolerability of antidepressant drugs (ADs) for the long-term treatment of depression.Method: The Cochrane Library was searched up to July 2006....

  • What's best for IBS? Oyola, Sonia; Rao, Goutham; Ewigman, Bernard // Clinician Reviews;Jan2013, Vol. 23 Issue 1, p24 

    The article presents a meta-analysis study which examined the usefulness of antidepressants and antispasmodics for treatment of irritable bowel syndrome (IBS). It presents the medical history of a 25-year old female patient who complained intermittent bouts of abdominal pains, constipation, gas,...

  • Efficacy of antidepressants of psychotherapy for functional bowel disorders. Dibaise, J.K. // American Journal of Gastroenterology;Dec2003, Vol. 98 Issue 12, p2592 

    Reports on the largest, randomized trial assessing the efficacy of desipramine (DES), a tricyclic antidepressant, and cognitive-behavioral therapy (CBT) against their placebo conditions for women with moderate to severe functional bowel disorders (FBD). Variables in the primary outcome measure...

  • Amitriptyline: still efficacious, but at what cost? Thompson, Chris // British Journal of Psychiatry;Feb2001, Vol. 178, p99 

    The article focuses the examination concerning efficacy of the antidepressant drug Amitriptyline. Researchers have claimed that Amitriptyline is still the leading antidepressant. Based on the randomized controlled trials (RCT), the drug has a small efficacy advantage over all other...

  • Black-Box Warnings.  // Antidepressants & Social Anxiety: A Pill for Shyness?;2007, p71 

    The article reports on the result of various studies which shows that the some children who are treated with antidepressants can experience increased suicidal thoughts and behaviors. The study, which involved nine different antidepressants, found out that none of the respondents committed...

  • Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases. Grover, Madhusudan; Camilleri, Michael // Journal of Gastroenterology;Feb2013, Vol. 48 Issue 2, p177 

    The effects of antidepressants on the gastrointestinal tract may contribute to their potential efficacy in functional dyspepsia and irritable bowel syndrome; buspirone, a prototype 5-HT1A agonist, enhances gastric accommodation and reduces postprandial symptoms in response to a challenge meal....

  • Fertility drugs, IBS and wheeze. Ford, Katrina // GP: General Practitioner;3/20/2009, p28 

    The article offers information on the latest medical studies in Great Britain. It notes on the positive effect to irritable bowel syndrome (IBS) patients for therapeutics using antidepressants and psychotherapies. It also includes on reduced calorie diets study which may result in weight loss in...

  • Furiex Pharmaceuticals Announces 1st Patient Dosed in Phase III Clinical Trials of MuDelta in Diarrhea-Predominant Irritable Bowel Syndrome.  // Biomedical Market Newsletter;6/25/2012, Vol. 21, p1 

    The article presents information that the first patient in Phase III randomized, double-blind, and placebo controlled studies, conducted by Furiex Pharmaceuticals Inc., has received a dose of MuDelta drug. It shows that the trials are meant to evaluate efficacy, safety and tolerability of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics